Subscribe
georgeclerk-1
georgeclerk / iStockphoto.com
27 September 2017Big Pharma

UK health committee to investigate pharma regulation after Brexit

The UK’s House of Commons has launched an investigation into post-Brexit regulatory agreements needed to guarantee the safe and effective supply of medicines and medical devices.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK life sciences receives £160m government funding
30 August 2017   The UK government has committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry.
Big Pharma
House of Lords hears evidence on life sciences and Brexit
17 October 2017   The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Big Pharma
UK life sciences receives £160m government funding
30 August 2017   The UK government has committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry.
Big Pharma
House of Lords hears evidence on life sciences and Brexit
17 October 2017   The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.

More on this story

Big Pharma
UK life sciences receives £160m government funding
30 August 2017   The UK government has committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry.
Big Pharma
House of Lords hears evidence on life sciences and Brexit
17 October 2017   The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages